IANNONE, LUIGI FRANCESCO
 Distribuzione geografica
Continente #
EU - Europa 1.130
NA - Nord America 958
AS - Asia 380
SA - Sud America 17
AF - Africa 7
OC - Oceania 3
Totale 2.495
Nazione #
US - Stati Uniti d'America 955
RU - Federazione Russa 749
IT - Italia 197
HK - Hong Kong 149
SG - Singapore 98
CN - Cina 79
IE - Irlanda 65
SE - Svezia 34
IN - India 21
FI - Finlandia 19
DE - Germania 17
GB - Regno Unito 15
JO - Giordania 13
BR - Brasile 10
JP - Giappone 10
FR - Francia 9
CH - Svizzera 8
CO - Colombia 5
CI - Costa d'Avorio 4
AT - Austria 3
AU - Australia 3
ES - Italia 3
MA - Marocco 3
TR - Turchia 3
AR - Argentina 2
GR - Grecia 2
ID - Indonesia 2
KR - Corea 2
LT - Lituania 2
MK - Macedonia 2
MX - Messico 2
NL - Olanda 2
PH - Filippine 2
PT - Portogallo 2
BE - Belgio 1
CA - Canada 1
TW - Taiwan 1
Totale 2.495
Città #
Santa Clara 488
Hong Kong 114
Singapore 78
Dublin 60
Ashburn 58
Moscow 54
Florence 26
Milan 21
Altamura 20
Lawrence 20
Mumbai 18
West Jordan 18
Chandler 16
Rome 16
Shanghai 16
Fontebuona 14
Helsinki 14
Beijing 11
Kent 10
Princeton 10
Bern 8
Boston 8
Nagoya 7
Fairfield 6
New York 6
São Paulo 6
Turin 6
Yubileyny 6
Brescia 5
Houston 5
Lappeenranta 5
Medford 5
San Mateo 5
Seattle 5
Washington 5
Woodbridge 5
Abidjan 4
Bremen 4
Fiesole 4
Livorno 4
Pontassieve 4
Bari 3
Barranquilla 3
Cambridge 3
Chicago 3
Davis 3
Fes 3
Hillsboro 3
Irvine 3
Istrana 3
Los Angeles 3
Paris 3
Prescot 3
San Diego 3
Sesto Fiorentino 3
Sydney 3
Vienna 3
Wilmington 3
Americana 2
Bad Durrheim 2
Bogotá 2
Boulder 2
Cavite City 2
Changsha 2
Cipolletti 2
Colombo 2
Council Bluffs 2
Forlì 2
Hefei 2
Impruneta 2
Kilburn 2
Krefeld 2
Laurel 2
Lisbon 2
London 2
Lucca 2
Lyon 2
Malappuram 2
Marseille 2
Nanjing 2
Naples 2
Nocera Umbra 2
Palermo 2
Pontedera 2
Reggio Emilia 2
San Giovanni Valdarno 2
Seoul 2
Skopje 2
Springfield 2
St Louis 2
Tacoronte 2
Thermi 2
Tokyo 2
Venice 2
Vilnius 2
Xiamen 2
York 2
Arezzo 1
Atlanta 1
Brussels 1
Totale 1.327
Nome #
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability 95
Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine 75
Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series 74
The trpa1 channel amplifies the oxidative stress signal in melanoma 74
The role of TRP ion channels in migraine and headache 71
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score 70
Tumor-Infiltrating Lymphocyte Recognition in Primary Melanoma by Deep Learning Convolutional Neural Network 69
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? 66
Emerging Pharmacological Treatments for Migraine in the Pediatric Population 64
COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report 64
Current status and future perspectives in HER2 positive advanced gastric cancer 61
The gut microbiome and efficacy of cancer immunotherapy 61
Gut microbiota manipulation as an epilepsy treatment 56
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study 55
Non-neuronal TRPA1 encodes mechanical allodynia associated with neurogenic inflammation and partial nerve injury in rats 55
Appropriate use of generic and branded antiseizure medications in epilepsy: Updated recommendations from the Italian League Against Epilepsy (LICE) 53
The Microbiome-Gut-Brain axis regulates social cognition & craving in young binge drinkers 52
The microbiota-gut-brain axis and epilepsy from a multidisciplinary perspective: Clinical evidence and technological solutions for improvement of in vitro preclinical models 52
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ) 51
Endometriosis and the diagnosis of different forms of migraine: an association with dysmenorrhoea 51
Microbiota-gut brain axis involvement in neuropsychiatric disorders 50
Spatial Proximity and Relative Distribution of Tumor-Infiltrating Lymphocytes and Macrophages Predict Survival in Melanoma 50
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine 47
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment 46
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy 43
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine 43
Status epilepticus in pregnancy: a literature review and a protocol proposal 42
Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome 42
Perineural invasion score system and clinical outcomes in resected pancreatic cancer patients 41
Clinically relevant drug interactions between statins and antidepressants 41
Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief 40
Assessing knowledge and attitudes toward epilepsy among schoolteachers and students: Implications for inclusion and safety in the educational system 39
Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY) 38
Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany 38
Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review 38
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study 37
A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report 37
Patterns of anti‐CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy 37
A real‐world comparison among third‐generation antiseizure medications: Results from the COMPARE study 36
Antiseizure medications for the prophylaxis of migraine during the anti-CGRP drugs era 34
Gut microbiota and psychogenic non-epileptic seizures: i can feel it in the belly 34
Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy 33
Can we 'seize' the gut microbiota to treat epilepsy? 32
Renal denervation for resistant hypertension 31
Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study 31
First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat 31
Migraine Treatment: Towards New Pharmacological Targets 30
Ixekizumab May Improve Renal Function in Psoriasis 30
Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs 29
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study 29
Management of status epilepticus in patients with liver or kidney disease: a narrative review 29
The potential role of interventions impacting on gut-microbiota in epilepsy 29
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 28
The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a "real world" context: focus on temporal lobe epilepsy 28
Immunotherapy-related biomarkers: Confirmations and uncertainties 27
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study 25
Totale 2.564
Categoria #
all - tutte 12.196
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.196


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202274 0 0 0 0 0 0 0 18 15 10 15 16
2022/2023314 13 51 15 9 1 37 35 12 16 29 68 28
2023/2024587 13 31 57 34 39 61 33 136 59 61 50 13
2024/20251.589 92 309 184 418 586 0 0 0 0 0 0 0
Totale 2.564